Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Style Narratives: A Survey of \Patterns and Styles Assessed\ Design - 2The Manual for Electric Vehicles that will be hot dealers in 2023
- 3How Would You Like to Deal with Your Funds?
- 4What you need to know about flu treatments as cases spike across the US
- 5Vote in favor of the bloom plan that adds a bit of excellence to your life!
- Top Music and Dance Celebration: Which One Gets You Going?
- Barry Manilow reveals lung cancer diagnosis and plans to undergo surgery: 'It's pure luck' it was 'found so early'
- James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- What is a Trump Gold Card? U.S. launches $1 million immigration visas
- Exclusive-Head of Pemex's production arm to step down in coming days, sources say
- Israel faces tough choices over haredi draft exemptions, legal expert warns
- Mobility exercises are an important part of fitness as we age. Here are some tips
- Spots to Go Hang Floating
- Geomagnetic storm grounds launch of Mars space weather satellites
